CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: WIPF2 (ImmuneEditome ID:147179)

1. Gene summary of enriched editing regions for WIPF2

check button Gene summary
Gene informationGene symbol

WIPF2

Gene ID

147179

GeneSynonymsWICH|WIRE
GeneCytomap

17q21.2

GeneTypeprotein-coding
GeneDescriptionWAS/WASL-interacting protein family member 2|WASP-binding protein|WASP-interacting protein-related protein|WIP- and CR16-homologous protein|WIP-related protein
GeneModificationdate20230329
UniprotIDQ8TF74;A8MWR2;J3KSA3;J3QQS0;J3QKM5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:40229204-40230294:+ENST00000494757.4ENSG00000171475.12WIPF2ncRNA_intronicL2b,AluSp,AluJo,AluSzchr17:40229204-40230294:+.alignment
chr17:40237325-40238396:+ENST00000494757.4ENSG00000171475.12WIPF2ncRNA_intronicAluSx,AluSc,AluSz,HAL1,AluSx1chr17:40237325-40238396:+.alignment
chr17:40257515-40257688:+ENST00000494757.4ENSG00000171475.12WIPF2ncRNA_intronicAluSzchr17:40257515-40257688:+.alignment
chr17:40257515-40257688:+ENST00000578304.1ENSG00000171475.12WIPF2ncRNA_intronicAluSzchr17:40257515-40257688:+.alignment
chr17:40263594-40264284:+ENST00000494757.4ENSG00000171475.12WIPF2ncRNA_intronicAluSz,L1MA7,AluSpchr17:40263594-40264284:+.alignment
chr17:40267677-40268006:+ENST00000494757.4ENSG00000171475.12WIPF2ncRNA_intronicAluSz6,AluJbchr17:40267677-40268006:+.alignment
chr17:40269151-40269515:+ENST00000494757.4ENSG00000171475.12WIPF2ncRNA_intronicAluJb,AluSx1chr17:40269151-40269515:+.alignment
chr17:40274427-40277655:+ENST00000323571.7ENSG00000171475.12WIPF2exonicAluJb,AluJr,Alu,AluSx,AluSx3,AluSx1,MIR3,(A)n,AluSc8,A-richchr17:40274427-40277655:+.alignment
chr17:40274427-40277655:+ENST00000394103.6ENSG00000171475.12WIPF2exonicAluJb,AluJr,Alu,AluSx,AluSx3,AluSx1,MIR3,(A)n,AluSc8,A-richchr17:40274427-40277655:+.alignment
chr17:40274427-40277655:+ENST00000583130.4ENSG00000171475.12WIPF2exonicAluJb,AluJr,Alu,AluSx,AluSx3,AluSx1,MIR3,(A)n,AluSc8,A-richchr17:40274427-40277655:+.alignment
chr17:40274427-40277655:+ENST00000583268.1ENSG00000171475.12WIPF2exonicAluJb,AluJr,Alu,AluSx,AluSx3,AluSx1,MIR3,(A)n,AluSc8,A-richchr17:40274427-40277655:+.alignment
chr17:40274427-40277655:+ENST00000585043.4ENSG00000171475.12WIPF2exonicAluJb,AluJr,Alu,AluSx,AluSx3,AluSx1,MIR3,(A)n,AluSc8,A-richchr17:40274427-40277655:+.alignment
chr17:40282891-40283570:+ENST00000323571.7ENSG00000171475.12WIPF2UTR3AluJr,AluSzchr17:40282891-40283570:+.alignment


Top

2. Tumor-specific enriched editing regions for WIPF2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:40282891-40283570:+BRCAEER4.2085e-03image
ENSG00000171475.12,WIPF2BRCAEAG4.2610e-03image
chr17:40282891-40283570:+COADEER7.2544e-08image
ENSG00000171475.12,WIPF2COADEAG2.8055e-08image
chr17:40282891-40283570:+HNSCEER6.0943e-03image
ENSG00000171475.12,WIPF2HNSCEAG6.2672e-03image
chr17:40282891-40283570:+LUADEER1.7638e-02image
ENSG00000171475.12,WIPF2LUADEAG1.6921e-02image
chr17:40282891-40283570:+LUSCEER2.2152e-05image
ENSG00000171475.12,WIPF2LUSCEAG2.0287e-05image
chr17:40282891-40283570:+PRADEER4.8780e-02image
chr17:40282891-40283570:+UCECEER1.3602e-03image
ENSG00000171475.12,WIPF2UCECEAG1.3513e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000171475.12,WIPF2BLCAPathEAG1.7468e-023.1003e-020.1150image
ENSG00000171475.12,WIPF2KIRPPathEAG4.0849e-024.9217e-030.1806image
chr17:40282891-40283570:+KIRPPathEER2.8595e-023.0797e-030.1899image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for WIPF2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:40282891-40283570:+GBMEERENSG00000153551,CMTM70.33212.7806e-035.8324e-100.4663imageNEIF4A3;HNRNPC;RBM10;TARDBP;U2AF2CMTM7MonocytesGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr17:40282891-40283570:+GBMEERENSG00000120742,SERP10.28111.5879e-026.6772e-080.4123imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAMacrophages_M0GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:40282891-40283570:+GBMEERENSG00000114251,WNT5A0.27791.7945e-021.6279e-070.4010imageNEIF4A3;HNRNPC;RBM10;TARDBP;U2AF2WNT5AMonocytesGSVA_HALLMARK_UV_RESPONSE_UP
chr17:40282891-40283570:+GBMEERENSG00000233971,RPS20P100.26462.5483e-024.2345e-110.4926imageNNNAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:40282891-40283570:+GBMEERENSG00000225259,ST13P60.24713.6582e-021.5018e-070.4020imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr17:40282891-40283570:+GBMEERENSG00000236992,RPL12L30.24474.3835e-021.3485e-090.4574imageNNNANK_cells_activatedGSVA_HALLMARK_APICAL_JUNCTION
chr17:40282891-40283570:+GBMEERENSG00000168374,ARF40.24124.8283e-022.3065e-090.4516imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAB_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V1
chr17:40282891-40283570:+ESCAEERENSG00000138080,EMILIN10.28003.9148e-021.8087e-080.4397imageNEIF4A3;TARDBP;U2AF2EMILIN1MonocytesGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results



Top

4. Enriched editing regions and immune related splicing for WIPF2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000171475.12,WIPF2
COADEAGESENSG00000188690.8chr10125796102:125796188:125798064:125798145:125807412:125807465-0.25083.6457e-021.1845e-09-0.4201imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_INFLAMMATORY_RESPONSE
ENSG00000171475.12,WIPF2
GBMEAGIRENSG00000155366.12chr1112705099:112705168:112705604:112705733-0.29031.6595e-021.0199e-06-0.4163imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL1;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
chr17:40282891-40283570:+
GBMEERA5ENSG00000198258.6chr199828591:9828675:9828326:9828376:9828326:98283890.26501.0782e-021.5953e-060.4155imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr17:40282891-40283570:+
GBMEERIRENSG00000197343.6chr799570198:99571792:99572244:99575536-0.29591.3959e-029.0790e-07-0.4122imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr17:40282891-40283570:+
GBMEERIRENSG00000155366.12chr1112705099:112705168:112705604:112705733-0.28921.4768e-021.0285e-06-0.4162imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
ENSG00000171475.12,WIPF2
GBMEAGA5ENSG00000198258.6chr199828591:9828675:9828326:9828376:9828326:98283890.26321.3780e-021.7647e-060.4139imageNAIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;METTL14;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr17:40282891-40283570:+
GBMEERIRENSG00000165802.15chr9137454390:137454443:137454537:137454656-0.27482.4794e-021.8841e-06-0.4098imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000171475.12,WIPF2
GBMEAGIRENSG00000165802.15chr9137454390:137454443:137454537:137454656-0.27572.7892e-021.8128e-06-0.4104imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000171475.12,WIPF2
GBMEAGIRENSG00000197343.6chr799570198:99571792:99572244:99575536-0.29691.5649e-028.8435e-07-0.4126imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr17:40282891-40283570:+
THYMEERA3ENSG00000101246.15chr2063702135:63702217:63701829:63701895:63701829:63701946-0.24381.7017e-023.2358e-06-0.4858imageNEIF4A3;HNRNPC;KHSRP;RBM10;TARDBP;U2AF2NAT_cells_CD4_naive

More results



Top

5. Enriched editing regions and immune infiltration for WIPF2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:40282891-40283570:+ACCEERT_cells_CD4_memory_resting1.2136e-02-0.5138image
ENSG00000171475.12,WIPF2ACCEAGT_cells_CD4_memory_resting1.2136e-02-0.5138image
chr17:40282891-40283570:+BLCAEERMacrophages_M14.8353e-050.2154image
ENSG00000171475.12,WIPF2BLCAEAGMacrophages_M18.0860e-050.2085image
chr17:40282891-40283570:+BRCAEERDendritic_cells_resting1.5217e-050.1510image
ENSG00000171475.12,WIPF2BRCAEAGDendritic_cells_resting1.6790e-050.1499image
chr17:40282891-40283570:+CHOLEERT_cells_CD4_memory_resting1.1841e-03-0.5905image
ENSG00000171475.12,WIPF2CHOLEAGT_cells_CD4_memory_resting1.9148e-03-0.5699image
chr17:40282891-40283570:+COADEERDendritic_cells_resting2.3681e-02-0.1641image
ENSG00000171475.12,WIPF2COADEAGDendritic_cells_resting1.5825e-02-0.1722image
chr17:40237325-40238396:+ESCAEERB_cells_naive1.2913e-02-0.4808image
chr17:40274427-40277655:+ESCAEERNeutrophils4.7788e-040.4338image
chr17:40282891-40283570:+ESCAEERT_cells_regulatory_(Tregs)5.0416e-03-0.2279image
ENSG00000171475.12,WIPF2ESCAEAGT_cells_regulatory_(Tregs)6.3166e-03-0.2206image
chr17:40282891-40283570:+GBMEERT_cells_CD4_naive2.4125e-02-0.1788image
ENSG00000171475.12,WIPF2GBMEAGT_cells_CD4_naive2.4183e-02-0.1787image
ENSG00000171475.12,WIPF2KICHEAGMast_cells_activated2.0941e-030.3959image
chr17:40282891-40283570:+KIRPEERMacrophages_M18.7773e-060.2688image
ENSG00000171475.12,WIPF2KIRPEAGMacrophages_M18.9581e-060.2685image
chr17:40282891-40283570:+LGGEERMonocytes8.8669e-04-0.1444image
ENSG00000171475.12,WIPF2LGGEAGMonocytes9.5552e-04-0.1435image
chr17:40282891-40283570:+LIHCEERNeutrophils5.4176e-030.2399image
ENSG00000171475.12,WIPF2LIHCEAGNeutrophils4.8999e-030.2426image
chr17:40282891-40283570:+LUADEERB_cells_naive3.6958e-02-0.1137image
ENSG00000171475.12,WIPF2LUADEAGB_cells_naive2.7522e-02-0.1195image
chr17:40282891-40283570:+LUSCEERMonocytes3.9886e-02-0.1240image
ENSG00000171475.12,WIPF2LUSCEAGMacrophages_M14.8278e-020.1190image
chr17:40282891-40283570:+MESOEERMonocytes9.7654e-03-0.3258image
ENSG00000171475.12,WIPF2MESOEAGMonocytes9.7654e-03-0.3258image
chr17:40282891-40283570:+PCPGEERNK_cells_activated3.3180e-020.1808image
ENSG00000171475.12,WIPF2PCPGEAGNK_cells_activated3.3639e-020.1803image
chr17:40282891-40283570:+PRADEERMacrophages_M15.6899e-040.1687image
ENSG00000171475.12,WIPF2PRADEAGMacrophages_M15.1537e-040.1697image
chr17:40282891-40283570:+SARCEERMast_cells_resting2.5939e-020.1789image
ENSG00000171475.12,WIPF2SARCEAGMast_cells_resting3.1870e-020.1725image
chr17:40257515-40257688:+STADEERT_cells_CD4_memory_resting2.7034e-02-0.3907image
chr17:40263594-40264284:+STADEERMacrophages_M12.2066e-020.2753image
chr17:40269151-40269515:+STADEERB_cells_memory1.4443e-020.5379image
chr17:40274427-40277655:+STADEERNK_cells_resting1.1614e-020.2502image
chr17:40282891-40283570:+STADEERT_cells_follicular_helper2.1610e-020.1290image
ENSG00000171475.12,WIPF2STADEAGT_cells_CD4_memory_activated2.5682e-020.1241image
chr17:40282891-40283570:+THCAEERDendritic_cells_resting2.9996e-050.1883image
ENSG00000171475.12,WIPF2THCAEAGDendritic_cells_resting3.3279e-050.1872image
chr17:40282891-40283570:+UCECEERNeutrophils6.1654e-030.2573image
ENSG00000171475.12,WIPF2UCECEAGNeutrophils6.4121e-030.2561image
ENSG00000171475.12,WIPF2UCSEAGEosinophils5.7627e-030.4341image


Top

6. Enriched editing regions and immune gene sets for WIPF2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr17:40282891-40283570:+KIRPEER5.5528e-03image5.7929e-030.1688image
ENSG00000171475.12,WIPF2KIRPEAG4.8122e-03image3.2923e-030.1796image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:40282891-40283570:+BLCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER8.2185e-060.2358image
ENSG00000171475.12,WIPF2BLCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.9080e-060.2507image
ENSG00000171475.12,WIPF2BRCAGSVA_HALLMARK_HEME_METABOLISMEAG3.5228e-080.1913image
chr17:40282891-40283570:+BRCAGSVA_HALLMARK_HEME_METABOLISMEER1.7506e-080.1959image
chr17:40282891-40283570:+CESCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.5187e-020.1519image
ENSG00000171475.12,WIPF2CESCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.2155e-020.1568image
ENSG00000171475.12,WIPF2CHOLGSVA_HALLMARK_SPERMATOGENESISEAG3.9409e-030.5362image
chr17:40282891-40283570:+CHOLGSVA_HALLMARK_SPERMATOGENESISEER1.3844e-020.4679image
ENSG00000171475.12,WIPF2COADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.5880e-060.3207image
chr17:40282891-40283570:+COADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.1848e-060.3357image
ENSG00000171475.12,WIPF2ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG5.9153e-030.2223image
chr17:40282891-40283570:+ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER5.8968e-030.2238image
chr17:40282891-40283570:+GBMGSVA_HALLMARK_PEROXISOMEEER6.5040e-030.2150image
ENSG00000171475.12,WIPF2GBMGSVA_HALLMARK_PEROXISOMEEAG6.3891e-030.2154image
ENSG00000171475.12,WIPF2HNSCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG3.8041e-050.2336image
chr17:40282891-40283570:+HNSCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER4.3737e-050.2318image
ENSG00000171475.12,WIPF2KICHGSVA_HALLMARK_COAGULATIONEAG8.7740e-030.3412image
ENSG00000171475.12,WIPF2KIRCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.9164e-020.1274image
chr17:40282891-40283570:+KIRCGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.6979e-020.1207image
ENSG00000171475.12,WIPF2KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.5760e-050.2614image
chr17:40282891-40283570:+KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.6916e-050.2501image
chr17:40282891-40283570:+LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEER7.1202e-04-0.1470image
ENSG00000171475.12,WIPF2LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEAG7.0938e-04-0.1470image
ENSG00000171475.12,WIPF2LIHCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.4474e-020.1746image
chr17:40282891-40283570:+LUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER8.9390e-040.1801image
ENSG00000171475.12,WIPF2LUADGSVA_HALLMARK_UV_RESPONSE_DNEAG1.1163e-030.1760image
chr17:40282891-40283570:+LUSCGSVA_HALLMARK_HYPOXIAEER1.2379e-020.1506image
ENSG00000171475.12,WIPF2LUSCGSVA_HALLMARK_HYPOXIAEAG2.0780e-020.1391image
chr17:40282891-40283570:+OVGSVA_HALLMARK_APOPTOSISEER1.3439e-020.1768image
ENSG00000171475.12,WIPF2OVGSVA_HALLMARK_APOPTOSISEAG2.0290e-030.2170image
chr17:40282891-40283570:+PAADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.6772e-040.2850image
ENSG00000171475.12,WIPF2PAADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.7511e-040.2847image
chr17:40282891-40283570:+PCPGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.9387e-02-0.1670image
chr17:40282891-40283570:+PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1407e-020.1058image
ENSG00000171475.12,WIPF2PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4339e-020.1105image
ENSG00000171475.12,WIPF2SARCGSVA_HALLMARK_MYC_TARGETS_V2EAG8.0279e-04-0.2665image
chr17:40282891-40283570:+SARCGSVA_HALLMARK_MYC_TARGETS_V2EER9.8473e-04-0.2621image
ENSG00000171475.12,WIPF2SKCMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG9.6476e-030.1711image
chr17:40282891-40283570:+SKCMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER9.5917e-030.1712image
chr17:40263594-40264284:+STADGSVA_HALLMARK_ADIPOGENESISEER2.0737e-040.4324image
chr17:40237325-40238396:+STADGSVA_HALLMARK_MYOGENESISEER2.0796e-040.4294image
ENSG00000171475.12,WIPF2STADGSVA_HALLMARK_UV_RESPONSE_UPEAG2.5273e-120.3766image
chr17:40274427-40277655:+STADGSVA_HALLMARK_ANGIOGENESISEER4.7166e-030.2790image
chr17:40282891-40283570:+STADGSVA_HALLMARK_UV_RESPONSE_UPEER6.4008e-090.3188image
chr17:40269151-40269515:+STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.2422e-030.6246image
chr17:40257515-40257688:+STADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.8490e-030.5291image
ENSG00000171475.12,WIPF2TGCTGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG5.5881e-030.3090image
chr17:40282891-40283570:+TGCTGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER5.2304e-030.3113image
ENSG00000171475.12,WIPF2THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.0263e-070.2243image
chr17:40282891-40283570:+THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.2118e-070.2240image
chr17:40282891-40283570:+THYMGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.3703e-020.2229image
ENSG00000171475.12,WIPF2THYMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.9518e-020.2283image
chr17:40282891-40283570:+UCECGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER7.4578e-040.3141image
ENSG00000171475.12,WIPF2UCECGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.3032e-030.3001image
ENSG00000171475.12,WIPF2UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.4192e-020.3604image


Top

7. Enriched editing regions and drugs for WIPF2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:40282891-40283570:+BLCAKU.55933EER2.1139e-07-0.2730image
ENSG00000171475.12,WIPF2BLCAKU.55933EAG6.8283e-08-0.2827image
ENSG00000171475.12,WIPF2BRCAEHT.1864EAG2.2272e-050.1477image
chr17:40282891-40283570:+BRCAEHT.1864EER4.5600e-050.1424image
chr17:40282891-40283570:+CESCEmbelinEER5.3852e-03-0.1738image
ENSG00000171475.12,WIPF2CESCEmbelinEAG6.3924e-03-0.1704image
ENSG00000171475.12,WIPF2CHOLCCT007093EAG2.9085e-040.6438image
chr17:40282891-40283570:+CHOLCCT007093EER8.0488e-050.6851image
chr17:40282891-40283570:+COADKU.55933EER1.6961e-05-0.3065image
ENSG00000171475.12,WIPF2COADKU.55933EAG1.0129e-04-0.2741image
ENSG00000171475.12,WIPF2ESCAGDC0941EAG8.3177e-04-0.2683image
chr17:40282891-40283570:+ESCABX.795EER6.0446e-04-0.2769image
ENSG00000171475.12,WIPF2GBMCGP.082996EAG1.3910e-04-0.2976image
chr17:40282891-40283570:+GBMCGP.082996EER1.4029e-04-0.2974image
ENSG00000171475.12,WIPF2HNSCJNJ.26854165EAG6.0154e-04-0.1954image
chr17:40282891-40283570:+HNSCJNJ.26854165EER6.4451e-04-0.1943image
ENSG00000171475.12,WIPF2KICHEHT.1864EAG5.1543e-030.3626image
ENSG00000171475.12,WIPF2KIRCEHT.1864EAG4.5238e-03-0.1543image
chr17:40282891-40283570:+KIRCEHT.1864EER4.6109e-03-0.1544image
ENSG00000171475.12,WIPF2KIRPBX.795EAG1.4885e-06-0.2901image
chr17:40282891-40283570:+KIRPBX.795EER2.0576e-06-0.2863image
ENSG00000171475.12,WIPF2LAMLAZD8055EAG4.7528e-030.4226image
chr17:40282891-40283570:+LGGGefitinibEER1.1362e-030.1414image
ENSG00000171475.12,WIPF2LGGGefitinibEAG1.2444e-030.1403image
ENSG00000171475.12,WIPF2LIHCAZD.2281EAG6.8509e-030.2370image
chr17:40282891-40283570:+LIHCAZD.2281EER6.9103e-030.2367image
chr17:40282891-40283570:+LUADCyclopamineEER6.5842e-03-0.1478image
ENSG00000171475.12,WIPF2LUADEmbelinEAG4.8256e-03-0.1525image
ENSG00000171475.12,WIPF2LUSCElesclomolEAG3.4370e-02-0.1274image
chr17:40282891-40283570:+LUSCElesclomolEER3.8157e-02-0.1251image
chr17:40282891-40283570:+OVEtoposideEER1.1773e-030.2307image
ENSG00000171475.12,WIPF2OVEtoposideEAG6.3582e-040.2395image
ENSG00000171475.12,WIPF2PAADCGP.60474EAG1.1643e-02-0.2076image
chr17:40282891-40283570:+PAADCGP.60474EER1.1718e-02-0.2074image
chr17:40282891-40283570:+PCPGCHIR.99021EER4.8462e-030.2376image
ENSG00000171475.12,WIPF2PCPGGSK269962AEAG4.9116e-030.2373image
chr17:40282891-40283570:+PRADBryostatin.1EER1.1075e-020.1247image
ENSG00000171475.12,WIPF2PRADBryostatin.1EAG1.7433e-020.1167image
ENSG00000171475.12,WIPF2READErlotinibEAG9.4802e-03-0.3148image
ENSG00000171475.12,WIPF2SARCLFM.A13EAG5.3635e-04-0.2749image
chr17:40282891-40283570:+SARCLFM.A13EER7.8326e-04-0.2670image
chr17:40282891-40283570:+STADAZ628EER6.2308e-06-0.2507image
chr17:40237325-40238396:+STADCyclopamineEER3.2084e-04-0.4206image
chr17:40257515-40257688:+STADBexaroteneEER1.3248e-02-0.4333image
chr17:40274427-40277655:+STADBortezomibEER3.6810e-04-0.3476image
chr17:40263594-40264284:+STADABT.263EER1.4891e-020.2921image
chr17:40269151-40269515:+STADKU.55933EER4.9310e-03-0.6025image
ENSG00000171475.12,WIPF2STADAZ628EAG2.4794e-07-0.2823image
chr17:40282891-40283570:+TGCTEmbelinEER2.3581e-02-0.2546image
ENSG00000171475.12,WIPF2TGCTEmbelinEAG2.6153e-02-0.2502image
chr17:40282891-40283570:+THCABIBW2992EER7.0282e-06-0.2024image
ENSG00000171475.12,WIPF2THCAKU.55933EAG6.8491e-06-0.2027image
chr17:40282891-40283570:+UCECFH535EER3.2162e-04-0.3338image
ENSG00000171475.12,WIPF2UCECFH535EAG6.9543e-04-0.3158image
chr17:40282891-40283570:+UVMEmbelinEER5.6425e-030.3859image
ENSG00000171475.12,WIPF2UVMEmbelinEAG5.6425e-030.3859image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType